Somewhat Favorable News Coverage Somewhat Unlikely to Impact Argos Therapeutics (ARGS) Stock Price
Press coverage about Argos Therapeutics (NASDAQ:ARGS) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Argos Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.1973710815529 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Argos Therapeutics traded up $0.10, hitting $0.27, during trading on Thursday, MarketBeat reports. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of -1.31. Argos Therapeutics has a 12 month low of $0.15 and a 12 month high of $10.40.
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings data on Monday, April 2nd. The biopharmaceutical company reported ($1.05) earnings per share for the quarter. The company had revenue of $1.67 million for the quarter.
Argos Therapeutics, Inc, an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.